<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack - Li, J - 2015 | Cochrane Library</title> <meta content="Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack - Li, J - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009938.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack - Li, J - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009938.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009938.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack" name="citation_title"/> <meta content="Jie Li" name="citation_author"/> <meta content="Junfeng Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Ming Liu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="wyplmh@hotmail.com" name="citation_author_email"/> <meta content="Shihong Zhang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Zilong Hao" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Jing Zhang" name="citation_author"/> <meta content="Xuanwu Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Canfei Zhang" name="citation_author"/> <meta content="The First Affiliated Hospital of Henan University of Science and Technology" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD009938.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009938.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009938.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009938.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Septal Occluder Device; Anticoagulants [*therapeutic use]; Fibrinolytic Agents [therapeutic use]; Foramen Ovale, Patent [complications, drug therapy, *therapy]; Ischemic Attack, Transient [etiology, *prevention &amp; control]; Platelet Aggregation Inhibitors [therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Secondary Prevention [*methods]; Stroke [etiology, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009938.pub2&amp;doi=10.1002/14651858.CD009938.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009938\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009938\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009938.pub2",title:"Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack",firstPublishedDate:"Sep 8, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009938.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009938.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009938.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009938.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009938.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009938.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009938.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009938.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009938.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009938.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2997 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009938.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/appendices#CD009938-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/table_n/CD009938StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/table_n/CD009938StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0002">Jie Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0003">Junfeng Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ming Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0005">Shihong Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0006">Zilong Hao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0007">Jing Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information#CD009938-cr-0008">Canfei Zhang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information/en#CD009938-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009938.pub2">https://doi.org/10.1002/14651858.CD009938.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009938-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009938-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009938-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009938-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009938-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009938-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009938-abs-0001" lang="en"> <section id="CD009938-sec-0001"> <h3 class="title" id="CD009938-sec-0001">Background</h3> <p>The optimal therapy for preventing recurrent stroke in people with cryptogenic stroke and patent foramen ovale (PFO) has not been defined. The choice between medical therapy (antithrombotic treatment with antiplatelet agents or anticoagulants) and transcatheter device closure has been the subject of intense debate over the past several years. Despite the lack of scientific evidence, a substantial number of people undergo transcatheter device closure (TDC) for secondary stroke prevention. </p> </section> <section id="CD009938-sec-0002"> <h3 class="title" id="CD009938-sec-0002">Objectives</h3> <p>To: 1) compare the safety and efficacy of TDC with best medical therapy alone for preventing recurrent stroke (fatal or non‐fatal) or transient ischemic attacks (TIAs) in people with PFO and a history of cryptogenic stroke or TIA; 2) identify specific subgroups of people most likely to benefit from closure for secondary prevention; and 3) assess the cost‐effectiveness of this strategy, if possible. </p> </section> <section id="CD009938-sec-0003"> <h3 class="title" id="CD009938-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (July 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> Issue 2, 2014), MEDLINE (1950 to July 2014) and EMBASE (1980 to July 2014). In an effort to identify unpublished and ongoing trials we searched seven trials registers and checked reference lists. </p> </section> <section id="CD009938-sec-0004"> <h3 class="title" id="CD009938-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs), irrespective of blinding, publication status, and language, comparing the safety and efficacy of device closure with medical therapy for preventing recurrent stroke or TIA in people with PFO and a history of cryptogenic stroke or TIA. </p> </section> <section id="CD009938-sec-0005"> <h3 class="title" id="CD009938-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, assessed quality and risk of bias, and extracted data. The primary outcome measures of this analysis were the composite endpoint of ischemic stroke or TIA events as well as recurrent fatal or non‐fatal ischemic stroke. Secondary endpoints included all‐cause mortality, serious adverse events (atrial fibrillation, myocardial infarction, bleeding) and procedural success and effective closure. We used the Mantel‐Haenszel method to obtain pooled risk ratios (RRs) using the random‐effects model regardless of the level of heterogeneity. We pooled data for the primary outcome measure with the generic inverse variance method using the random‐effects model, yielding risk estimates as pooled hazard ratio (HR), which accounts for time‐to‐event outcomes. </p> </section> <section id="CD009938-sec-0006"> <h3 class="title" id="CD009938-sec-0006">Main results</h3> <p>We included three RCTs involving a total of 2303 participants: 1150 participants were randomized to receive TDC and 1153 participants were randomized to receive medical therapy. Overall, the risk of bias was regarded as high. The mean follow‐up period of all three included trials was less than five years. Baseline characteristics (age, sex, and vascular risk factors) were similar across trials. Intention‐to‐treat analyses did not show a statistically significant risk reduction in the composite endpoint of recurrent stroke or TIA in the TDC group when compared with medical therapy (RR 0.73, 95% CI 0.45 to 1.17). A time‐to‐event analysis combining the results of two RCTs also failed to show a significant risk reduction with TDC (HR 0.69, 95% CI 0.43 to 1.13). When assessing stroke prevention alone, TDC still did not show a statistically significant benefit (RR 0.61, 95% CI 0.29 to 1.27) (HR 0.55, 95% CI 0.26 to 1.18). In a sensitivity analysis including the two studies using the Amplatzer PFO occluder, TDC showed a possible protective effect on recurrent stroke compared with medical therapy (HR 0.38, 95% CI 0.14 to 1.02); however, it did not reach statistical significance. Safety analysis found that the overall risks for all‐cause mortality and adverse events were similar in both the TDC and medical therapy groups. However, TDC increased the risk of new‐onset atrial fibrillation (RR 3.50, 95% CI 1.47 to 8.35) and may be associated with the type of device used. </p> </section> <section id="CD009938-sec-0007"> <h3 class="title" id="CD009938-sec-0007">Authors' conclusions</h3> <p>The combined data from recent RCTs have shown no statistically significant differences between TDC and medical therapy in the prevention of recurrent ischemic stroke. TDC closure was associated with an increased risk of atrial fibrillation but not with serious adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009938-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009938-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009938-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009938-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009938-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD009938-abs-0006">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009938-abs-0005" lang="en"> <h3>Patent foramen ovale closure versus medical therapy for preventing further stroke or similar events in people who have had a stroke of unknown cause </h3> <p><b>Question:</b> We wanted to compare the safety and effectiveness of transcatheter device closure (TDC) versus medical therapy in people with a patent foramen ovale (PFO) who have suffered a stroke of unknown cause in order to prevent strokes or similar events occurring again. </p> <p><b>Background:</b> Some people who have had a stroke of no known cause (cryptogenic stroke) are found to have a PFO, which is a hole between the upper chambers of the heart. It is believed that the existence of a PFO may cause further strokes or similar events so it is important to close the PFO to prevent this from happening. It is not clear whether using TDC (by placing a device over the hole in the heart via a tube that is inserted through a vein in the groin) is superior to medical therapy for preventing recurrent stroke or other similar events. </p> <p><b>Study characteristics:</b> The evidence is current to July 2014. We included in our analysis three multicenter randomized trials involving a total of 2303 participants. All three trials recruited participants aged 60 years or younger with a cryptogenic stroke or minor stroke and had a PFO diagnosed by specialist heart scan. 1150 participants were randomized to the TDC group where the procedure was performed with the Amplatzer device in two studies, and with the STARFlex device in one study. The mean follow‐up period of all three included trials was less than five years. Two studies were sponsored by St Jude Medical and one study was sponsored by NMT Medical. </p> <p><b>Key results:</b> We found that, when compared with medical therapy, TDC failed to show any significant benefit in reducing the risk of recurrent stroke or similar events. However, there was a possible protective effect on recurrent strokes in those participants for whom an Amplatzer device was used compared with medical therapy. We did not find evidence that TDC increased the rate of serious adverse events overall. However, TDC increased the risk of new‐onset atrial fibrillation (where there is a problem with the rate or rhythm of the heartbeat) and may be associated with the type of device used. </p> <p><b>Quality of the evidence:</b> We performed this systematic review of three randomized trials to compare both the safety and efficacy of TDC with medical therapy on recurrent cerebrovascular events in people with cryptogenic stroke and PFO following the <i>Cochrane Handbook for Systematic Reviews of Interventions.</i> The major problem in terms of risk of bias is the high dropout rate compared with event rate in these three trials and different dropout rates between groups. Meanwhile, we lack individual‐level data for analysis. Although there is a suggestion of potential benefit with the Amplatzer device closure in preventing recurrent stroke, our findings still need to be confirmed in further studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009938-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009938-sec-0082"></div> <h3 class="title" id="CD009938-sec-0083">Implications for practice</h3> <section id="CD009938-sec-0083"> <p>In our meta‐analysis, the combined data from recent RCTs have shown no statistically significant differences. The Amplatzer device closure showed a trend of protective effect in recurrent stroke compared with medical therapy but this was associated with a significantly increased risk of atrial fibrillation. Transcatheter device closure is a safe treatment option without significantly increasing the rate of serious adverse events. However, it appears that device closure increases the risk of new onset atrial fibrillation and might be associated with the type of device used. Nonetheless, there was a trend towards reducing recurrent stroke in those people using the Amplatzer device, there were still some potential risks of bias in the three included RCTs and some limitations in the process of our meta‐analysis, and our findings need to be confirmed in further studies. If in fact there was a long‐lasting protective benefit from device closure, then the clinical benefit could be substantial. However, potential risks of an implanted device could also accumulate over time. Indeed, for a young person who had already suffered a PFO‐related stroke, it is still too early for a final conclusion regarding choosing PFO closure or long‐term antithrombotic therapy. </p> </section> <h3 class="title" id="CD009938-sec-0084">Implications for research</h3> <section id="CD009938-sec-0084"> <p>Ongoing PFO closure trials (such as <a href="./references#CD009938-bbs2-0007" title="MasJL . Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2007. ">CLOSE 2007</a>, <a href="./references#CD009938-bbs2-0008" title="SongJK , LeeJY . Device closure versus medical therapy for cryptogenic stroke patients with high‐risk patent foramen ovale (DEFENSE‐PFO)  . ClinicalTrials.gov (http://www.ClinicalTrials.gov)2012. ">DEFENSE‐PFO 2012</a>, and <a href="./references#CD009938-bbs2-0009" title="KasnerSE , RhodesJF , SondergaardL , ThomassenL . GORE HELEX septal occluder for patent foramen ovale (PFO) closure in stroke patients (Gore REDUCE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2008. ">Gore REDUCE 2008</a>) and registries (such as the RoPE study) may provide further insight into the controversial issue of PFO closure in people with cryptogenic stroke or TIA and guide clinicians to the proper selection of closure device and people who may benefit. As we know, the STARFlex device (NMT Medical) is no longer commercially available because of the higher complication rate and lower procedural success rate. PFO closure studies such as <a href="./references#CD009938-bbs2-0005" title="HansenCS , TonderN , IversenKK . The effect of device closure of patent foramen ovale in elderly patients with cryptogenic stroke/TCI. ClinicalTrials.gov (http://www.ClinicalTrials.gov)2009. ">CryptoCard 2009</a> (NCT01018355) have been terminated due to an unsatisfactory recruitment rate. Meanwhile, newer closure devices are under investigation (buttoned device, Angel wings, bio‐absorbable devices), which aim to eliminate procedural complications and increase effectiveness. Further appropriately designed randomized trials with large sample sizes, long‐term follow‐up and participant‐level pooling are needed to determine the true effects of PFO closure compared with medical therapy, with respect to the prevention of recurrent stroke. </p> <p>However, there are several unavoidable challenges to the future design of RCTs in PFO closure, including low event rate, the need for long‐term follow‐up to accumulate events, off‐label implantation and the fact that other mechanisms than paradoxical embolism might come into play, and so on. For the above reason, we think a well‐designed prospective, open, controlled registry with long‐term follow‐up might play an important role in resolving the issue in future research. In addition, closure of a PFO was associated with a reduction in moderate, large, and massive infarcts in a post‐hoc analysis of <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> so that closure may have an effect on improving the functional outcome of people who suffer from recurrent stroke. Further studies should also consider people's quality of life as a possible outcome measure. Findings of future research, especially for updated meta‐analysis including further data from ongoing RCTs, would be of substantial interest and great importance in better understanding the benefits and risks of PFO closure in people with cryptogenic stroke. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009938-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009938-sec-0029"></div> <div class="table" id="CD009938-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.45 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1323<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (25 to 64) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (26 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.47</b> <br/> (0.17 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>414<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (9 to 69) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (9 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009938-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: recurrent stroke (non‐fatal or fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.29 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (9 to 40) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (10 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.4</b> <br/> (0.14 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1394<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (5 to 40) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (5 to 39) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009938-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome: all‐cause mortality at the end of follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.23 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 16) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome:total serious adverse events at the end of follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.88 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b> <br/> (166 to 231) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> <br/> (155 to 216) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome: the incidence of atrial fibrillation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.5</b> <br/> (1.47 to 8.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> <br/> (15 to 87) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> <br/> (15 to 84) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009938-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack </p> <p><b>Settings:</b> hospital, medical center </p> <p><b>Intervention:</b> TDC </p> <p><b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for recurrent stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.55</b> </p> <p>(0.26 to 1.18)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for recurrent stroke stratified by the type of device ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.38</b> </p> <p>(0.14 to 1.02)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1394<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for composite of recurrent stroke or TIA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.69</b> </p> <p>(0.43 to 1.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1323<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.45</b> <br/> (0.16 to 1.28) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval;<b>HR:</b> hazard ratio </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009938-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009938-sec-0030"></div> <p>Stroke is the second most common cause of death and the leading cause of disability worldwide (<a href="./references#CD009938-bbs2-0038" title="LiuM , WuB , WangWZ , LeeLM , ZhangSH , KongLZ . Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurology2007;6(5):456‐64. ">Liu 2007</a>). The incidence of stroke appears to be increasing, and the associated economic costs are staggering. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee showed that in the United States the estimated direct and indirect cost of stroke for 2009 was USD 68.9 billion, with a mean per capita lifetime cost of USD 140,048 (<a href="./references#CD009938-bbs2-0039" title="Lloyd‐JonesD , AdamsR , CarnethonM , DeSimoneG , FergusonTB , FlegalK , et al. Heart disease and stroke statistics ‐ 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2009;119(3):e21‐181. ">Lloyd‐Jones 2009</a>). Approximately 80% of all strokes are ischemic (<a href="./references#CD009938-bbs2-0023" title="DonnanGA , FisherM , MacleodM , DavisSM . Stroke. Lancet2008;371(9624):1612‐23. ">Donnan 2008</a>). Of these, about 25% to 40% have no identifiable cause even after extensive evaluation and are designated as cryptogenic stroke (CS) (<a href="./references#CD009938-bbs2-0010" title="AdamsHP , BendixenBH , KappelleJ , BillerJ , LoveBB , GordonDL , et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST.Trial of Org 10172 in Acute Stroke Treatment. Stroke1993;24(1):35–41. ">Adams 1993</a>; <a href="./references#CD009938-bbs2-0027" title="GrauAJ , WeimarC , BuggleF , HeinrichA , GoertlerM , NeumaierS , et al. Risk factors, outcome, and treatment subtypes of ischemic stroke: the German stroke data bank. Stroke2001;32(11):2559‐66. ">Grau 2001</a>; <a href="./references#CD009938-bbs2-0037" title="LeeBC , HwangSH , JungS , YuKH , LeeJH , ChoSJ , et al. The Hallym Stroke Registry: a web‐based stroke data bank with an analysis of 1,654 consecutive patients with acute stroke. European Neurology2005;54(2):81‐7. ">Lee 2005</a>; <a href="./references#CD009938-bbs2-0050" title="PettyGW , Brown JrRD , WhisnantJP , SicksJD , O'FallonWM , WiebersDO . Ischemic stroke subtypes. A population‐based study of incidence and risk factor. Stroke1999;30(12):2513‐6. ">Petty 1999</a>; <a href="./references#CD009938-bbs2-0056" title="SaccoRL , EllenbergJH , MohrJP , TatemichiTK , HierDB , PriceTR , et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Annals of Neurology1989;25(4):382‐90. ">Sacco 1989</a>). </p> <section id="CD009938-sec-0031"> <h3 class="title" id="CD009938-sec-0031">Description of the condition</h3> <p>A patent foramen ovale (PFO) is an embryonic defect in the interatrial septum. It may or may not be associated with an atrial septal aneurysm, and is defined as an aneurysm associated with a PFO that has a 10 mm or greater excursion of the septum (<a href="./references#CD009938-bbs2-0025" title="FurieKL , KasnerSE , AdamsRJ , AlbersGW , BushRL , FaganSC , et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2011;42:227‐76. [DOI: 10.1161/STR.0b013e3181f7d043] ">Furie 2011</a>). PFO is found in 24% of healthy adults and 38% of people with cryptogenic stroke. This suggests a causal relationship between PFO and cryptogenic stroke (<a href="./references#CD009938-bbs2-0041" title="MattleHP , MeierB , NedeltchevK . Prevention of stroke in patients with patent foramen ovale. International Journal of Stroke2010;5(2):92‐102. ">Mattle 2010</a>). A meta‐analysis derived from case‐control studies confirmed the association of PFO with stroke both when strokes are compared with non‐stroke controls and when cryptogenic strokes are checked against strokes of known cause, especially in people younger than 55 years of age (<a href="./references#CD009938-bbs2-0047" title="OverellJR , BoneI , LeesKR . Interatrial septal abnormalities and stroke: a meta‐analysis of case–control studies. Neurology2000;55(8):1172–9. ">Overell 2000</a>). However, in another systematic review of 23 case‐control studies, about one‐third of discovered PFOs in people with cryptogenic stroke are likely to be incidental, and this probability is sensitive to patient characteristics such as age and the presence of an atrial septal aneurysm (<a href="./references#CD009938-bbs2-0014" title="Alsheikh‐AliAA , ThalerDE , KentDM . Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?. Stroke2009;40(7):2349‐55. ">Alsheikh‐Ali 2009</a>). Although there appears to be an association between PFO and cryptogenic stroke in case‐control studies, the cohort studies are less persuasive (<a href="./references#CD009938-bbs2-0020" title="DiTullioMR , SaccoRL , SciaccaRR , JinZ , HommaS . Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. Journal of the American College of Cardiology2007;49(7):797–802. ">Di Tullio 2007</a>; <a href="./references#CD009938-bbs2-0042" title="MeissnerI , KhandheriaBK , HeitJA , PettyGW , ShepsSG , SchwartzGL , et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population‐based study. Journal of the American College of Cardiology2006;47(2):440‐5. ">Meissner 2006</a>). Regarding the evidence for 'causality' in the association between PFO and cryptogenic ischemic stroke, a recent meta‐analysis that focused on high quality studies found there to be a rather weak association providing less evidence for causality overall (<a href="./references#CD009938-bbs2-0018" title="DavisD , GregsonJ , WilleitP , StephanB , Al‐Shahi SalmanR , BrayneC . Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta‐analysis of association studies. Neuroepidemiology2013;40(1):56‐67. ">Davis 2013</a>). </p> <p>People with PFO and a history of cryptogenic stroke are at risk of recurrence despite medical treatment, a risk that is reported particularly in people with PFO and associated atrial septal aneurysm (<a href="./references#CD009938-bbs2-0063" title="WindeckerS , WahlA , NedeltchevK , ArnoldM , SchwerzmannM , SeilerC , et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Journal of the American College of Cardiology2004;44(4):750‐8. ">Windecker 2004</a>). Paradoxical embolism has been identified as the most likely stroke mechanism and describes a condition whereby emboli of venous origin enter the systemic circulation from the right to the left atrium via a PFO (<a href="./references#CD009938-bbs2-0014" title="Alsheikh‐AliAA , ThalerDE , KentDM . Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?. Stroke2009;40(7):2349‐55. ">Alsheikh‐Ali 2009</a>). In addition, two more probable mechanisms of stroke for PFO patients should be considered. These are PFO or atrial septal aneurysm‐induced thrombogenicity; or left atrium clot formation from atrial arrhythmias that may occur in association with a PFO or atrial septal aneurysm (<a href="./references#CD009938-bbs2-0040" title="MaronBA , ShekarPS , GoldhaberSZ . Paradoxical embolism. Circulation2010;122(19):1968‐72. ">Maron 2010</a>). Meanwhile, anatomical variants of the PFO and the atrium (for example the size of PFO, associated atrial septal aneurysm, etc) and the coexistence of thrombotic or pre‐thrombotic conditions have been identified as possible cofactors in increasing the risk of stroke from a PFO (<a href="./references#CD009938-bbs2-0021" title="DiTullioMR , HommaS . Patent foramen ovale and stroke: what should be done?. Current Opinion in Hematology2009;16(5):391‐6. ">Di Tullio 2009</a>). Therefore, therapeutic measures for secondary prevention are intended to eliminate thrombus formation, paradoxical embolism, or both (<a href="./references#CD009938-bbs2-0063" title="WindeckerS , WahlA , NedeltchevK , ArnoldM , SchwerzmannM , SeilerC , et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Journal of the American College of Cardiology2004;44(4):750‐8. ">Windecker 2004</a>). </p> </section> <section id="CD009938-sec-0032"> <h3 class="title" id="CD009938-sec-0032">Description of the intervention</h3> <p>Since paradoxical embolization from a thrombus present in the venous system is the major putative mechanism of the association between PFO and stroke, antithrombotic strategies have been adopted to reduce the risk of recurrent events in people with a PFO (<a href="./references#CD009938-bbs2-0021" title="DiTullioMR , HommaS . Patent foramen ovale and stroke: what should be done?. Current Opinion in Hematology2009;16(5):391‐6. ">Di Tullio 2009</a>). Treatment choices include medical therapy with antiplatelet agents or vitamin K antagonists, percutaneous device closure, or open surgical repair. Whereas suture closure of an incidental PFO is performed routinely during the course of an operation undertaken for another indication, primary surgical repair is rarely advocated at the present time (<a href="./references#CD009938-bbs2-0045" title="O'GaraPT , MesseSR , TuzcuEM , CathaG , RingJC . Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trial. Journal of the American College of Cardiology2009;53(21):2014‐8. ">O'Gara 2009</a>). An early meta‐analysis, published in 2001, of five retrospective cohort studies evaluating therapeutic options (antiplatelet therapy, warfarin, or surgery) suggested that warfarin was superior to antiplatelet therapy and comparable to surgical closure for preventing recurrent cerebral ischemic events in people with PFO (<a href="./references#CD009938-bbs2-0046" title="OrgeraMA , O'MalleyPG , TaylorAJ . Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta‐analysis. Southern Medical Journal2001;94(7):699‐703. ">Orgera 2001</a>). However, with the development of interventional technologies in recent years PFO closure has become a feasible and relatively safe treatment option, with a high implant success rate and a low incidence of periprocedural complications reported in observational studies (<a href="./references#CD009938-bbs2-0035" title="KoR , WalkerNE , MullenMJ . Different patent foramen ovale closure techniques in varying anatomies. Interventional Cardiology2010;2(1):85‐95. ">Ko 2010</a>). The Amplatzer Septal Occluder, the STARFlex septal closure system and the Gore‐Helex Septal Occluder are commonly used devices for PFO occlusion (<a href="./references#CD009938-bbs2-0058" title="TaaffeM , FischerE , BaranowskiA , MajunkeN , HeinischC , LeetzM , et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer® versus CardioSEAL®‐STARflex® versus HELEX® occluder). American Journal of Cardiology2008;101(9):1353–8. ">Taaffe 2008</a>). </p> </section> <section id="CD009938-sec-0033"> <h3 class="title" id="CD009938-sec-0033">How the intervention might work</h3> <p>Percutaneous device closure of PFO, which closes off the conduit of the possible paradoxical embolism, is less invasive than open‐heart surgery. While it avoids the need for long‐term anticoagulation, there is increasing evidence on success rates, occurrence of complications, and recurrent neurological events associated with this approach (<a href="./references#CD009938-bbs2-0065" title="WöhrleJ . Closure of patent foramen ovale after cryptogenic stroke. Lancet2006;368(9533):350‐2. [DOI: 10.1016/S0140‐6736(06)69087‐9] ">Wöhrle 2006</a>). Several cohort studies have indicated that interventional PFO closure appears to be a safe and promising technique in people with symptomatic PFO and is associated with a low incidence of peri‐interventional complications and recurrent thromboembolic events (<a href="./references#CD009938-bbs2-0012" title="AlameddineF , BlockPC . Transcatheter patent foramen ovale closure for secondary prevention of paradoxical embolic events: acute results from the FORECAST registry. Catheterization and Cardiovascular Interventions2004;62(4):512‐6. ">Alameddine 2004</a>; <a href="./references#CD009938-bbs2-0015" title="BraunM , GliechV , BoscheriA , SchoenS , GahnG , ReichmannH , et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: periprocedural safety and mid‐term follow‐up results of three different device occluder systems. European Heart Journal2004;25(5):424‐30. ">Braun 2004</a>; <a href="./references#CD009938-bbs2-0019" title="DeCillisE , BasileDP , AcquavivaT , DeBlasiR , PetruzzellisM , BortoneAS . Abstract 8807: Efficacy and effectiveness evaluation of secondary prevention of cryptogenic stroke or TIA in patients with PFO successfully treated by percutaneous approach: six years follow‐up. Circulation2010; Vol. 122:A8807. ">De Cillis 2010</a>; <a href="./references#CD009938-bbs2-0030" title="HongTE , ThalerD , BrorsonJ . Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate‐term results of the US multicenter clinical trial. Catheterization and Cardiovascular Interventions2003;60(4):524‐8. ">Hong 2003</a>). However, it should be appreciated that PFO closure devices are not without complications. Major complications from percutaneous intervention occur in 1.5% of people and include embolization of the device from the septum; malposition of the device; trigger of arrhythmias, infection, and cardiac perforation; and erosion at the site of device implantation (<a href="./references#CD009938-bbs2-0026" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , et al. Study design of the CLOSURE I trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex Septal Closure System versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke2010;41:2872‐83. ">Furlan 2010</a>). </p> <p>In a meta‐analysis of non‐randomized studies (including 10 studies of transcatheter closure and six studies of medical therapy), PFO closure was associated with a decreased risk of recurrent stroke or transient ischemic attack (TIA) compared with medical treatment (<a href="./references#CD009938-bbs2-0032" title="KhairyP , O'DonnellCP , LandzbergMJ . Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli. Annals of Internal Medicine2003;139(9):753‐60. ">Khairy 2003</a>). However, due to the inability to adjust for between‐group differences in baseline clinical characteristics, follow‐up, and outcome assessment, the use of analyses of observational data to answer questions about therapeutic efficacy is not recommended (<a href="./references#CD009938-bbs2-0013" title="AlmekhlafiMA , WiltonSB , RabiDM , GhaliWA , LorenzettiDL , HillMD . Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta‐analysis. Neurology2009;73(2):89‐97. ">Almekhlafi 2009</a>). </p> </section> <section id="CD009938-sec-0034"> <h3 class="title" id="CD009938-sec-0034">Why it is important to do this review</h3> <p>To date, the optimal therapy for preventing recurrent stroke in people with cryptogenic stroke and PFO has not been defined. The choice between medical therapy (antithrombotic treatment with antiplatelet agents or anticoagulants) and percutaneous device closure has been the subject of intense debate over the past several years. The therapy recommendations were largely based on non‐randomized studies (<a href="./references#CD009938-bbs2-0059" title="TamayoA , HarrerJU . Patent foramen ovale and ischemic stroke recurrence: the end of a never‐ending story?. Neurology2009;73(2):84‐5. ">Tamayo 2009</a>). According to the recent American Heart Association/American Stroke Association (AHA/ASA) guidelines, published in 2010, aspirin is recommended for secondary ischemic event prevention in people with PFO, and insufficient data exist to establish whether anticoagulation is equivalent or superior to aspirin for secondary stroke prevention in people with PFO. Meanwhile, insufficient data exist to make a recommendation about PFO closure in people with a first stroke and a PFO (<a href="./references#CD009938-bbs2-0025" title="FurieKL , KasnerSE , AdamsRJ , AlbersGW , BushRL , FaganSC , et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2011;42:227‐76. [DOI: 10.1161/STR.0b013e3181f7d043] ">Furie 2011</a>). Despite the lack of scientific evidence, a substantial number of people undergo percutaneous device closure for secondary stroke prevention (<a href="./references#CD009938-bbs2-0062" title="WeimarC , HolleDN , BenemannJ , SchmidE , SchminkeU , HaberlRL , et al. Current management and risk of recurrent stroke in cerebrovascular patients with right‐to‐left cardiac shunt. Cerebrovascular Diseases2009;28(4):349‐56. ">Weimar 2009</a>). </p> <p>Currently, at least five large randomized controlled trials (RCTs) comparing the safety and efficacy of PFO closure with that of medical therapy are ongoing (<a href="./references#CD009938-bbs2-0040" title="MaronBA , ShekarPS , GoldhaberSZ . Paradoxical embolism. Circulation2010;122(19):1968‐72. ">Maron 2010</a>). At the same time, many clinical studies about this issue are published worldwide. These studies set out to determine if the benefits of PFO closure in cryptogenic stroke outweigh the risks, for example the FORI study that was published recently suggested that PFO closure might be superior to medical therapy for the prevention of recurrent stroke; periprocedural complications were the trade‐off for this clinical benefit (<a href="./references#CD009938-bbs2-0048" title="PaciaroniM , AgnelliG , BertoliniA , PezziniA , PadovaniA , CasoV , et al. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovascular Diseases2010;31(2):109‐16. ">Paciaroni 2010</a>). Meanwhile, people with PFO and a history of cryptogenic stroke are a heterogeneous group for which a substantial proportion of those PFOs are likely to be incidental and would not benefit from PFO closure. As a result, participant selection is of great importance in therapeutic decision‐making (<a href="./references#CD009938-bbs2-0060" title="ThalerDE , KentDM . Rethinking trial strategies for stroke and patent foramen ovale. Current Opinion in Neurology2010;23(1):73‐8. ">Thaler 2010</a>). Therefore, the aim of this review is to systematically evaluate all the RCTs that focus on this issue to make an objective comparison of the relative safety and efficacy of these respective approaches, identify the specific subgroups most likely to benefit from closure, and assess the cost‐effectiveness of this strategy, if possible. This will provide the best available evidence for clinical practice and further research planning for secondary prevention of stroke in people with PFO and a history of cryptogenic stroke or TIA. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009938-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009938-sec-0035"></div> <p>To: 1) compare the safety and efficacy of TDC with best medical therapy alone for preventing recurrent stroke (fatal or non‐fatal) or transient ischemic attacks (TIAs) in people with PFO and a history of cryptogenic stroke or TIA; 2) identify specific subgroups of people most likely to benefit from closure for secondary prevention; and 3) assess the cost‐effectiveness of this strategy, if possible. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009938-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009938-sec-0036"></div> <section id="CD009938-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009938-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs), irrespective of blinding, publication status, and language, comparing the safety and efficacy of transcatheter device closure (TDC) with medical therapy for preventing recurrent stroke (fatal or non‐fatal) or transient ischemic attack (TIA) in people with patent foramen ovale (PFO) and a history of cryptogenic stroke or TIA. </p> </section> <section id="CD009938-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included trials that recruited participants:</p> <p> <ul id="CD009938-list-0001"> <li> <p>of any age or sex;</p> </li> <li> <p>with a diagnosis of cryptogenic stroke (defined as ischemic stroke with the absence of any other identifiable cause despite a thorough evaluation) or TIA; </p> </li> <li> <p>with the presence of PFO (determined by a positive bubble study utilizing transesophageal echocardiography (TEE) or transthoracic echocardiography (TTE) and demonstrating spontaneous right‐to‐left shunting or right‐to‐left shunting during Valsalva maneuver) with or without atrial septal aneurysm (<a href="./references#CD009938-bbs2-0017" title="CarpenterDA , FordAL , LeeJM . Patent foramen ovale and stroke: should PFOs be closed in otherwise cryptogenic stroke?. Current Atherosclerosis Reports2010;12(4):251‐8. [DOI: 10.1007/s11883‐010‐0114‐7] ">Carpenter 2010</a>; <a href="./references#CD009938-bbs2-0022" title="DiTullioMR . Patent foramen ovale: echocardiographic detection and clinical relevance in stroke. Journal of the American Society of Echocardiography2010;23(2):144‐55. ">Di Tullio 2010</a>); </p> </li> <li> <p>grade 3 or less on the modified Rankin Scale (mRS).</p> </li> </ul> </p> <p>The included trials excluded those people with any identifiable cause for a thromboembolic event other than PFO and those with other medical problems that would either lead to inability to complete the trial or interfere with the assessment of outcomes. </p> </section> <section id="CD009938-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included trials evaluating TDC of PFO (regardless of type and pattern of transcatheter device, for example the Amplatzer Septal Occluder, STARFlex septal closure system, Gore‐Helex Septal Occluder) (<a href="./references#CD009938-bbs2-0040" title="MaronBA , ShekarPS , GoldhaberSZ . Paradoxical embolism. Circulation2010;122(19):1968‐72. ">Maron 2010</a>) versus best medical therapy alone. Best medical therapy is defined as medical antithrombotic treatment during the follow‐up period using an antiplatelet agent or anticoagulant or both. </p> <p>We compared:</p> <p> <ul id="CD009938-list-0002"> <li> <p>TDC versus aspirin;</p> </li> <li> <p>TDC versus warfarin (with a target International Normalized Ratio (INR) of 2.0 to 3.0 and where heparin was only permitted during the initial warfarin treatment period in order to provide sufficient anticoagulation); </p> </li> <li> <p>other comparisons if possible (TDC versus clopidogrel, TDC versus aspirin plus dipyridamole, etc). </p> </li> </ul> </p> </section> <section id="CD009938-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009938-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009938-list-0003"> <li> <p>Composite endpoint of ischemic stroke (fatal or non‐fatal) or TIA events.</p> </li> <li> <p>Recurrent fatal or non‐fatal ischemic stroke.</p> </li> </ul> </p> </section> <section id="CD009938-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009938-list-0004"> <li> <p>All‐cause post‐randomization mortality (cardiovascular and non‐cardiovascular death during the scheduled follow‐up period). </p> </li> <li> <p>Adverse events directly related to the device, procedure, or medical therapy during the follow‐up: device or catheterization‐related complications, bleeding complications, hospitalizations related to PFO or its treatment, new arrhythmias or conduction abnormality, acute myocardial infarction, etc. </p> </li> <li> <p>Assessment of PFO closure by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE). </p> </li> <li> <p>Cost‐effectiveness if analyzed by the included trials.</p> </li> </ul> </p> </section> </section> </section> <section id="CD009938-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html" target="_blank">Cochrane Stroke Group</a> module. We searched for relevant trials in all languages and arranged translation of relevant papers published in languages other than English. </p> <section id="CD009938-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic bibliographic databases:</p> <p> <ul id="CD009938-list-0005"> <li> <p>Cochrane Stroke Group Trials Register (July 2014);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, Issue 2, 2014) (<a href="./appendices#CD009938-sec-0088">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (1950 to July 2014) (<a href="./appendices#CD009938-sec-0089">Appendix 2</a>); </p> </li> <li> <p>EMBASE (1980 to July 2014) (<a href="./appendices#CD009938-sec-0090">Appendix 3</a>). </p> </li> </ul> </p> <p>We developed the search strategies in consultation with the Cochrane Stroke Group Trials Search Co‐ordinator and adapted the MEDLINE search strategy for the other databases. </p> <p>We also searched the following ongoing trial and research registers (July 2014):</p> <p> <ul id="CD009938-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>); </p> </li> <li> <p>Current Controlled Trials Register (<a href="http://www.controlled-trials.com/" target="_blank">http://www.controlled‐trials.com/</a>); </p> </li> <li> <p>Stroke Trials Registry (<a href="http://www.strokecenter.org/trials/" target="_blank">http://www.strokecenter.org/trials/</a>); </p> </li> <li> <p>CenterWatch (<a href="http://www.centerwatch.com/" target="_blank">http://www.centerwatch.com/</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>); </p> </li> <li> <p>CardioSource (<a href="http://www.cardiosource.org/" target="_blank">http://www.cardiosource.org/</a>); </p> </li> <li> <p>Chinese Clinical Trial Registry, ChiCTR (<a href="http://www.chictr.org/" target="_blank">http://www.chictr.org/</a> ) </p> </li> </ul> </p> </section> <section id="CD009938-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of relevant trials and recent reviews.</p> </section> </section> <section id="CD009938-sec-0047"> <h3 class="title" id="CD009938-sec-0047">Data collection and analysis</h3> <section id="CD009938-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Li J, Liu J) independently screened the titles, abstracts and keywords of all records identified by the searches of the electronic bibliographic databases and excluded obviously irrelevant articles. We then obtained the full texts of the remaining articles to determine which studies met the inclusion criteria. We resolved any disagreements through discussion and, if necessary, negotiated with a third review author (Liu M) who served as an arbitrator. We obtained translations of trials in languages other than English and contacted authors for further information where necessary. For excluded trials we recorded the reasons for exclusion. </p> </section> <section id="CD009938-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (Li J, Zhang J) independently extracted data from all the included trials using a standard data extraction form. We recorded the following data: trial characteristics, methodology, participant characteristics, intervention characteristics, and outcomes. We resolved disagreements through discussion until we reached a consensus, or with a third review author (Liu M) arbitrating as necessary. For dichotomous outcomes we extracted the number of participants experiencing the event and the total number of participants in each arm of the trial. For continuous outcomes we extracted the mean value and standard deviation for the changes in each arm of the trial along with the total number in each group. </p> </section> <section id="CD009938-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (Li J, Liu J) independently assessed each study for risk of bias using Cochrane's tool for assessing risk of bias as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009938-bbs2-0029" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We created 'Risk of bias' tables and included a description and a judgement (low risk of bias, high risk of bias, or unclear risk of bias) for the following points for each of the included studies: </p> <p> <ul id="CD009938-list-0007"> <li> <p>Random sequence generation;</p> </li> <li> <p>Allocation concealment;</p> </li> <li> <p>Blinding of participants and personnel;</p> </li> <li> <p>Blinding of outcome assessment;</p> </li> <li> <p>Incomplete outcome data;</p> </li> <li> <p>Selective reporting;</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We resolved any disagreements between review authors through discussion, with a third author (Liu M) serving as an arbitrator if necessary. </p> </section> <section id="CD009938-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed the size of the treatment effect for dichotomous outcomes as risk ratios (RRs) or risk differences (RDs) with 95% confidence interval (CI), and we expressed results for continuous outcomes as mean differences (MDs) (if the same scale for each trial was available) or standardized mean differences (SMDs) (if different scales were used) with 95% CI. With continuous outcomes, we intended to compare the changes between groups after randomization and at the end of the follow‐up period. We pooled data for the primary outcome measure with the generic inverse variance method using the random‐effects model, yielding risk estimates as hazard ratios, which account for time‐to‐event. </p> </section> <section id="CD009938-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>For each included study, we reviewed the level at which randomization occurred and took this into consideration in the analysis. In the case of studies with non‐standard design (for example cross‐over trials, cluster‐randomized trials), we managed the data according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009938-bbs2-0029" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009938-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>If data were missing, we documented the missing data for each study and attempted to contact the investigators or companies of the relevant trials for additional information. If some data remained unavailable, we considered both best‐case and worst‐case scenarios. </p> </section> <section id="CD009938-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for statistical heterogeneity among the results of different studies using the Chi² test with significance set at P less than 0.1. We used the I² statistic, which describes the percentage of variation between trial results due to heterogeneity, with a value greater than 50% indicating substantial heterogeneity. We sought the potential sources of the heterogeneity (clinical heterogeneity and methodological heterogeneity). We performed meta‐analysis using the random‐effects model regardless of the level of heterogeneity. </p> </section> <section id="CD009938-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not use funnel plots or the Egger test to assess the existence of possible publication bias because there were only three trials included in our meta‐analysis (<a href="./references#CD009938-bbs2-0024" title="EggerM , Davey‐SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> <section id="CD009938-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses for all data using Review Manager 5 (<a href="./references#CD009938-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We performed all analyses in accordance with the intention‐to‐treat (ITT) method. </p> </section> <section id="CD009938-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If appropriate data were available we planned to perform the following subgroup analyses:</p> <p> <ul id="CD009938-list-0008"> <li> <p>Participant characteristics: age; sex; history of previous stroke or TIA;</p> </li> <li> <p>Additional history of previous vascular events;</p> </li> <li> <p>Timing of intervention (transcatheter device closure) after stroke onset;</p> </li> <li> <p>The size of the PFO and degree of functional shunting;</p> </li> <li> <p>PFO with or without atrial septal aneurysm;</p> </li> <li> <p>Different types and patterns of transcatheter devices;</p> </li> <li> <p>Risk factors predisposing participants to a recurrent stroke due to a mechanism other than paradoxical embolism; </p> </li> <li> <p>Length of the follow‐up period.</p> </li> </ul> </p> </section> <section id="CD009938-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We identified issues regarded as appropriate for a sensitivity analysis, for example method of randomization, blinding of outcome assessment, intention‐to‐treat analysis, design of study. We conducted sensitivity analyses: </p> <p> <ul id="CD009938-list-0009"> <li> <p>excluding studies with inadequate concealment of allocation;</p> </li> <li> <p>excluding studies in which outcome evaluation was not blinded;</p> </li> <li> <p>excluding studies in which loss to follow‐up was not reported or was greater than 10%; </p> </li> <li> <p>by performing meta‐analysis using both fixed‐effect and random‐effects models;</p> </li> <li> <p>by re‐analyzing the data by removing studies with non‐standard designs if such studies were included; </p> </li> <li> <p>by re‐analyzing the data by removing studies with assumed values to replace missing data. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009938-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009938-sec-0059"></div> <section id="CD009938-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD009938-sec-0061"> <h4 class="title">Results of the search</h4> <p>See <a href="./references#CD009938-sec-0098" title="">Characteristics of included studies</a>; <a href="./references#CD009938-sec-0100" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD009938-sec-0101" title="">Characteristics of ongoing studies</a>. </p> <p>We searched MEDLINE and EMBASE from 1950 to July 2014, and after duplicates were removed we identified 1251 references. A full search of the Cochrane Central Register of Controlled Trials (CENTRAL) identified 65 references and we received data on 13 trials from the Cochrane Stroke Group Trials Register for assessment. Searches of clinical trials databases identified a further three potential studies. We found nine relevant RCTs (<a href="./references#CD009938-bbs2-0004" title="MooneyMR . CARDIA STAR trial: a United States randomized clinical trial of the CARDIA STAR patent foramen ovale closure system. http://www.mplsheart.com/pages/Research.asp?ID=10&amp;SID=28 (accessed by the Cochrane Stroke Group 2006). ">CARDIA STAR 2006</a>; <a href="./references#CD009938-bbs2-0007" title="MasJL . Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2007. ">CLOSE 2007</a>; <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>; <a href="./references#CD009938-bbs2-0005" title="HansenCS , TonderN , IversenKK . The effect of device closure of patent foramen ovale in elderly patients with cryptogenic stroke/TCI. ClinicalTrials.gov (http://www.ClinicalTrials.gov)2009. ">CryptoCard 2009</a>; <a href="./references#CD009938-bbs2-0008" title="SongJK , LeeJY . Device closure versus medical therapy for cryptogenic stroke patients with high‐risk patent foramen ovale (DEFENSE‐PFO)  . ClinicalTrials.gov (http://www.ClinicalTrials.gov)2012. ">DEFENSE‐PFO 2012</a>; <a href="./references#CD009938-bbs2-0009" title="KasnerSE , RhodesJF , SondergaardL , ThomassenL . GORE HELEX septal occluder for patent foramen ovale (PFO) closure in stroke patients (Gore REDUCE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2008. ">Gore REDUCE 2008</a>; <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; <a href="./references#CD009938-bbs2-0006" title="RosinL , BergerF . PEPSIS: Paraoxial Embolism Prevention Study in Ischemic Stroke. PEPSIS Trial Website (http://www.pepsis.stroke‐trial.com) (accessed by the Cochrane Stroke Group 2002). ">PEPSIS 2002</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>). We excluded one trial because the participants did not have cryptogenic stroke (<a href="./references#CD009938-bbs2-0004" title="MooneyMR . CARDIA STAR trial: a United States randomized clinical trial of the CARDIA STAR patent foramen ovale closure system. http://www.mplsheart.com/pages/Research.asp?ID=10&amp;SID=28 (accessed by the Cochrane Stroke Group 2006). ">CARDIA STAR 2006</a>). Three trials that met the criteria for inclusion in the analysis were completed and published (<a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>; <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>). One trial had insufficient data to determine whether it met the criteria for inclusion and it was placed in studies awaiting classification (<a href="./references#CD009938-bbs2-0006" title="RosinL , BergerF . PEPSIS: Paraoxial Embolism Prevention Study in Ischemic Stroke. PEPSIS Trial Website (http://www.pepsis.stroke‐trial.com) (accessed by the Cochrane Stroke Group 2002). ">PEPSIS 2002</a>). Another trial, which was terminated due to an unsatisfactory enrolment rate with no publications provided, is awaiting classification (<a href="./references#CD009938-bbs2-0005" title="HansenCS , TonderN , IversenKK . The effect of device closure of patent foramen ovale in elderly patients with cryptogenic stroke/TCI. ClinicalTrials.gov (http://www.ClinicalTrials.gov)2009. ">CryptoCard 2009</a>). Three trials are still ongoing (<a href="./references#CD009938-bbs2-0007" title="MasJL . Patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence (CLOSE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2007. ">CLOSE 2007</a>; <a href="./references#CD009938-bbs2-0008" title="SongJK , LeeJY . Device closure versus medical therapy for cryptogenic stroke patients with high‐risk patent foramen ovale (DEFENSE‐PFO)  . ClinicalTrials.gov (http://www.ClinicalTrials.gov)2012. ">DEFENSE‐PFO 2012</a>; <a href="./references#CD009938-bbs2-0009" title="KasnerSE , RhodesJF , SondergaardL , ThomassenL . GORE HELEX septal occluder for patent foramen ovale (PFO) closure in stroke patients (Gore REDUCE). ClinicalTrials.gov (http://www.ClinicalTrials.gov)2008. ">Gore REDUCE 2008</a>). See study flow diagram (<a href="#CD009938-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009938-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009938-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009938-sec-0062"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD009938-sec-0098" title="">Characteristics of included studies</a>. </p> <p>The three studies included were all multicenter RCTs. <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> was conducted at 87 sites and <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> at 69 sites in the USA and Canada; the third study was conducted at 29 sites in Europe, Canada, Brazil, and Australia (<a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>). The three trials recruited a combined total of 2303 participants, aged 60 years or younger with a cryptogenic stroke or TIA and had a PFO by means of transesophageal echocardiography. They all excluded people with any identified potential cause of ischemic stroke or TIA other than the PFO. Baseline characteristics, such as age, sex, and cardiovascular risk factors, were similar between treatment groups in all the studies. In total, 1150 participants were randomized to closure of the PFO performed with the Amplatzer PFO Occluder (St Jude Medical) in two studies (<a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>); and with the STARFlex device (NMT Medical) in one study (<a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>). In the three studies, the medical treatments were different: in <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> the participants in the closure group were given a standard antiplatelet regimen, including clopidogrel 75 mg/day for six months, and aspirin 81 to 325 mg/day for two years after the procedure; participants assigned to medical therapy were given warfarin (with a target INR of 2.0 to 3.0), aspirin (325 mg/day) or both, at the discretion of the principal investigator at each site. Participants in the closure group in <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a> adopted recommended antithrombotic treatment including acetylsalicylic acid 100 to 325 mg/day for at least five to six months, and ticlopidine 250 to 500 mg/day or clopidogrel 75 to 150 mg/day for one to six months; in the medical group antithrombotic treatment was left to the discretion of the treating physician including antiplatelet therapy or oral anticoagulation. The participants in the closure group of <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> received aspirin 81 to 325 mg plus clopidogrel for one month, followed by aspirin monotherapy for five months. Subsequently, antiplatelet therapy was administered at the discretion of the site investigator in the medical therapy group. Five medical therapies were allowed throughout <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>: aspirin (223 participants, 46.5%), warfarin (121 participants, 25.2%), clopidogrel (67 participants, 14.0%), aspirin with extended‐release dipyridamole (39 participants, 8.1%), and aspirin with clopidogrel (30 participants, 6.2%). Assessments of clinical endpoints and adverse events were planned at 1, 6, 12, 18, and 24 months and annually thereafter. A transesophageal echocardiogram was obtained at the six‐month visit for participants in the closure group in the three included studies. The mean follow‐up period of all three included trials was less than five years, and varied across studies (4.1 years in the closure group and 4.0 years in the medical therapy group for <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>, 2.0 years for <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>, and 2.6 ± 2.0 years for <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>). All the included studies reported time‐to‐event outcomes using Cox proportional hazard ratios (HRs). </p> </section> <section id="CD009938-sec-0063"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD009938-sec-0099" title="">Characteristics of excluded studies</a>. </p> <p>We excluded one study, because the participants included all types of stroke, not only cryptogenic stroke (<a href="./references#CD009938-bbs2-0004" title="MooneyMR . CARDIA STAR trial: a United States randomized clinical trial of the CARDIA STAR patent foramen ovale closure system. http://www.mplsheart.com/pages/Research.asp?ID=10&amp;SID=28 (accessed by the Cochrane Stroke Group 2006). ">CARDIA STAR 2006</a>). </p> </section> </section> <section id="CD009938-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>Comments on potential biases in individual studies are reported in the 'Risk of bias' tables of the <a href="./references#CD009938-sec-0098" title="">Characteristics of included studies</a> section. The findings are displayed in <a href="#CD009938-fig-0002">Figure 2</a> and <a href="#CD009938-fig-0003">Figure 3</a>. All studies except <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> had adequate generation of random sequence and allocation concealment. In none of the studies were participants blinded to the intervention. However, all the outcome assessors were blinded. The greatest risk of bias came from the high rate of participants lost to follow‐up and withdrawal from assigned therapy, as well as the difference in the dropout rate between the closure and medical therapy groups: 1.8% in the closure group and 0.7% in the medical therapy group in <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>; 15.2% and 20.0% in <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; 9.2% and 17.2% in <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>. Although all three included studies clearly reported the number of participants who withdrew from the study and were lost to follow‐up, and performed the intention‐to‐treat analyses, the high dropout rate compared with event rate, and the difference in the dropout rate between the closure and medical therapy groups, could still lead to a high risk of attrition bias. The study authors of <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a> reported a possible risk of selective reporting bias, which was introduced because the Clinical Events Committee discounted potential primary endpoint events more often in the medical therapy group than in closure group; risk of selective reporting bias in the other two studies was unclear. We did not use funnel plots and the Egger test to assess the existence of possible publication bias because there were only three trials included in our meta‐analysis. However, publication bias is unlikely as all three included RCTs had negative results. </p> <div class="figure" id="CD009938-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009938-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD009938-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009938-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD009938-sec-0065"> <h3 class="title" id="CD009938-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD009938-tbl-0001"><b>Summary of findings for the main comparison</b> TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</a>; <a href="./full#CD009938-tbl-0002"><b>Summary of findings 2</b> TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</a>; <a href="./full#CD009938-tbl-0003"><b>Summary of findings 3</b> TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</a>; <a href="./full#CD009938-tbl-0004"><b>Summary of findings 4</b> TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</a> </p> <section id="CD009938-sec-0066"> <h4 class="title">1.1 Primary outcome measure: composite endpoint of ischemic stroke (non‐fatal or fatal) or TIA </h4> <p>No fatal strokes occurred in either group in the three included studies. Two studies—<a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> and <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>—presented a composite endpoint of recurrent stroke or TIA based on the ITT method, showing that there was no statistically significant difference in the prevention of composite cerebrovascular events in people with PFO and a history of cryptogenic stroke or TIA when comparing device closure with medical therapy (RR 0.73, 95% CI 0.45 to 1.17) (<a href="./references#CD009938-fig-0004" title="">Analysis 1.1</a>). Meanwhile, a pooled hazard ratio (HR), which accounted for time‐to‐event outcomes in the ITT cohort, also failed to show a statistically significant protective effect of closure compared with medical therapy (HR 0.69, 95% CI 0.43 to 1.13) (<a href="./references#CD009938-fig-0018" title="">Analysis 4.1</a>). </p> </section> <section id="CD009938-sec-0067"> <h4 class="title">1.2 Primary outcome measure: recurrent non‐fatal or fatal ischemic stroke</h4> <p>As reported in <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>, only major stroke was adjudicated as the primary composite endpoint. Minor stroke was taken into consideration, one participant in the closure group and seven participants in the medical group had a stroke (HR 0.14, 95% CI 0.02 to 1.17). Overall, recurrent stroke occurred in 22 of 1150 participants randomized to the device closure group and 36 of 1153 participants randomized to the medical therapy group. The RR for recurrent stroke (RR 0.61, 95% CI 0.29 to 1.27) did not confer an advantage of PFO closure over medical therapy in the ITT cohort (<a href="./references#CD009938-fig-0012" title="">Analysis 2.2</a>). Similarly, a pooled HR which accounted for time‐to‐event in the ITT cohort also suggested that there was no significant difference between closure and medical therapy in preventing recurrent stroke (HR 0.55, 95% CI 0.26 to 1.18) (<a href="./references#CD009938-fig-0011" title="">Analysis 2.1</a>). In a sensitivity analysis including the two studies using the Amplatzer device, PFO closure did not result in a statistically significant reduction in the risk of recurrent stroke compared with medical therapy (RR 0.40, 95% CI 0.14 to 1.19). However, the result of a pooled HR account for time‐to‐event analysis showed a trend towards a protective effect (HR 0.38, 95% CI 0.14 to 1.02), nonetheless there was no significant subgroup interaction to support significant differences between the groups. </p> </section> <section id="CD009938-sec-0068"> <h4 class="title">1.3 Subgroup analyses for the composite outcome</h4> <p>We performed subgroup analyses to investigate specific characteristics of participants with PFO that were at high risk and most likely to benefit from closure for secondary prevention. Age: less than 45 years (RR 0.46, 95% CI 0.12 to 1.72), 45 years or more (RR 0.72, 95% CI 0.28 to 1.83); gender: male (RR 0.51; 95% CI 0.26 to 1.01), female (RR 1.04, 95% CI 0.56 to 1.91); atrial septal aneurysm (ASA): presence of ASA (RR 0.71, 95% CI 0.22 to 2.27), absence of ASA (RR 0.78, 95% CI 0.47 to 1.29); the shunt size of PFO: trace or moderate (RR 0.90, 95% CI 0.52 to 1.56), substantial (RR 0.37, 95% CI 0.09 to 1.45); the entry vascular events: stroke (RR 0.77, 95% CI 0.48 to 1.23), TIA or systemic embolism (RR 0.66, 95% CI 0.30 to 1.44); baseline medical regimen: antiplatelet alone (RR 0.61, 95% CI 0.29 to 1.30), anticoagulant alone (RR 0.93, 95% CI 0.28 to 3.07) did not influence treatment effect of PFO closure (<a href="./references#CD009938-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD009938-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD009938-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD009938-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD009938-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD009938-fig-0010" title="">Analysis 1.7</a>). Male participants with a substantial shunt size randomized to the PFO closure group had a tendency towards decreasing cerebral vascular events when compared with medical therapy. However, we found no significant tests of interaction regarding gender and shunt size (the P value tested for subgroup difference were 0.13 and 0.23 respectively). </p> </section> <section id="CD009938-sec-0069"> <h4 class="title">2.1 Secondary outcome: all‐cause mortality at the end of follow‐up</h4> <p>In <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> there were two deaths in the closure group and four deaths in the medical therapy group. However, no deaths were found to be caused by stroke or related to the device or procedure. In <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a> two participants died (one caused by chronic obstructive pulmonary disease and another caused by a glioma) in the closure group and no participants died in the medical therapy group, which was included in the analysis of the primary composite endpoint. In <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>, three deaths in the device group and six in the medical therapy group occurred after the early post‐randomization period and were adjudicated as not study‐related. Overall analysis of the three included studies shows that there was no significant difference in the incidence of all‐cause mortality comparing closure with medical groups (RR 0.65, 95% CI 0.23 to 1.84) (<a href="./references#CD009938-fig-0013" title="">Analysis 3.1</a>). </p> </section> <section id="CD009938-sec-0070"> <h4 class="title">2.2 Secondary outcome: total serious adverse events at the end of follow‐up</h4> <p>Safety analyses were performed on the ITT cohort. There was no significant difference in the rates of total serious adverse events between the closure and medical groups (RR 1.04, 95% CI 0.88 to 1.23), regardless of the type of PFO closure device used: STARFlex septal closure system (RR 0.92, 95% CI 0.68 to 1.25) and Amplatzer PFO occluder (RR 1.10, 95% CI 0.90 to 1.34) (<a href="./references#CD009938-fig-0014" title="">Analysis 3.2</a>). </p> <section id="CD009938-sec-0071"> <h5 class="title">2.2.1 Atrial fibrillation</h5> <p>In <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>, atrial fibrillation occurred in 23 participants in the closure group and in three participants in the medical therapy group. Of the 23 participants, atrial fibrillation occurred in 14 (61%) within 30 days after the implantation procedure. In <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>, new‐onset atrial fibrillation was observed in six participants in the closure group and in two participants in the medical therapy group, including one periprocedural episode. In <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>, the total incidence of atrial fibrillation did not differ significantly between the two groups: 15 of 499 participants (3.0%) and seven of 481 participants (1.5%) respectively, of which two were adjudicated as procedure or device related. The overall incidence of atrial fibrillation was significantly higher in the closure group when compared with the medical therapy group (RR 3.50, 95% CI 1.47 to 8.35). When stratified by the type of device, the STARFlex septal closure system had a higher risk of causing atrial fibrillation (RR 7.92, 95% CI 2.40 to 26.21) compared with the Amplatzer PFO occluder (RR 2.27, 95% CI 1.05 to 4.94) ( <a href="./references#CD009938-fig-0015" title="">Analysis 3.3</a>). However, there was no significant subgroup interaction between the different device trials. </p> </section> <section id="CD009938-sec-0072"> <h5 class="title">2.2.2 Myocardial infarction</h5> <p>Two studies using the Amplatzer device presented an incidence of myocardial infarction between the two groups based on the ITT method (<a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>). In the pooled analysis of these two studies, we found no significant difference in the incidence of myocardial infarction between the closure and medical groups (RR 2.85; 95% CI 0.44 to 18.67) (<a href="./references#CD009938-fig-0016" title="">Analysis 3.4</a>). </p> </section> <section id="CD009938-sec-0073"> <h5 class="title">2.2.3 Bleeding</h5> <p>A total of 36 episodes of bleeding (20 in the closure group and 16 in the medical therapy group) were reported in all three included studies. The overall frequency of bleeding events did not differ significantly between the two groups (RR 1.46, 95% CI 0.47 to 4.55), regardless of the type of PFO closure device used: STARFlex septal closure system (RR 2.58, 95% CI 0.82 to 8.18) and Amplatzer PFO occluder (RR 1.05, 95% CI 0.21 to 5.13) (<a href="./references#CD009938-fig-0017" title="">Analysis 3.5</a>). </p> </section> </section> <section id="CD009938-sec-0074"> <h4 class="title">2.3 Procedural success and effective closure</h4> <p>All three included studies reported the rate of procedural success (defined as successful implantation of one or more closure devices with no procedural complication) and effective closure in the closure group (defined as closure with no or trace residual shunt). In <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> the procedure using the STARFlex septal closure system was successful in 362 (89.4%) participants. At six months, 315 (86.1%) of 366 participants in the closure group underwent transesophageal echocardiography (TEE) and were documented as effective closure. At two years, effective closure was maintained in 320 of the 369 participants who underwent TEE (86.7%). In <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>, the procedure using the Amplatzer PFO occluder was deemed to be successful in 188 of the 196 participants (95.9%). Effective closure was achieved in 142 of the 148 participants who underwent TEE at six months (95.9%). In <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> the rate of procedural success using the Amplatzer device was 96.1%. At six months, 93.5% of the participants in the closure group met the criteria for effective closure. </p> </section> <section id="CD009938-sec-0075"> <h4 class="title">3 Cost‐effectiveness of TDC</h4> <p>We did not perform our own cost‐effectiveness analysis because these outcomes have been evaluated in another study that performed a detailed cost analysis by pooling data from the three published RCTs comparing PFO closure with medical therapy (<a href="./references#CD009938-bbs2-0051" title="PickettC , VillinesT , FergusonM , HultenE . Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;D=emed11&amp;AN=71512311] ">Pickett 2014</a>).The authors calculated cost per life‐year (LY) gained and per quality adjusted life‐year (QALY) gained by PFO closure and used the commonly accepted Medicare cost‐effectiveness threshold of less than USD 50,000/QALY‐gained.They found that at 31.0 years (29.6 to 33.6), the per‐patient mean cost of medical therapy exceeded that of PFO closure. Among studies utilizing only the Amplatzer device, the cost analysis more strongly favored closure: cost to prevent one stroke USD 652,392 (USD 318,955 to USD 26,888,272); time to less than USD 50,000/QALY‐gained, 2.4 years (1.3 to 10.1); time to medical cost exceeding closure cost, 22.7 years (19.75 to 26.7). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009938-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009938-sec-0076"></div> <section id="CD009938-sec-0077"> <h3 class="title" id="CD009938-sec-0077">Summary of main results</h3> <p>In this systematic review, which included 2303 participants, the device closure of patent foramen ovale was not associated with a significantly lower risk of the composite endpoint of recurrent stroke or transient ischemic attacks (TIA) compared with medical therapy in participants with a history of cryptogenic stroke or TIA (risk ratio (RR) 0.73, 95% confidence interval (CI) 0.45 to 1.17). A time‐to‐event analysis combining the results of two randomized controlled trials (RCTs) also failed to show a significant risk reduction with transcatheter device closure (TDC) (hazard ratio (HR) 0.69, 95% CI 0.43 to 1.13). Moreover, when assessing for stroke prevention alone, device closure did not show a statistically significant benefit. However, when we conducted a sensitivity analysis evaluating the impact of patent foramen ovale (PFO) closure on recurrent stroke separately in two studies using the Amplatzer PFO occluder versus one study using the STARFlex septal closure system, we found that although the direction of the effect of Amplatzer PFO occluder on recurrent strokes compared with medical therapy was beneficial, the confidence intervals are too wide to exclude no difference (HR 0.38, 95% CI 0.14 to 1.02). The test for subgroup differences with the results of the study using the STARFlex device was not statistically significant. </p> <p>In our analyses, we also explored specific characteristics of participants most likely to benefit from closure for secondary prevention that have been suggested as "high risk PFO" in observational studies, such as younger age, presence of atrial septal aneurysm, substantial shunt size, etc, based on available data from the included RCTs for their primary outcomes. We found none of the subgroups suggested a significant effect on the primary outcome. Selected subgroups, such as men with substantial shunt size, will probably benefit from device closure on recurrent events. However, no significant tests of interaction were found (both P values greater than 0.10 for interaction) and this result could be easily explained by chance and has low credibility. </p> <p>In addition, we performed safety analysis and found that the overall risks for all‐cause mortality and adverse events were similar in both the device closure and the medical therapy groups. The incidence of bleeding and myocardial infarction were also not significantly different between the two groups. The incidence of atrial fibrillation was found to be higher in the device closure group compared with the medical therapy group. Of note, when stratified by the type of device used both the STARFlex and Amplatzer device increased the risk of atrial fibrillation compared with medical therapy, although the risk of developing atrial fibrillation was more than three times higher with the STARFlex device. Furthermore, implantation of the Amplatzer PFO occluder was associated with a high rate of procedural success with minimal or no residual shunt, when compared with the STARFlex septal closure system. However, it is notable that there is no significant subgroup interaction between the different device trials. </p> <p>We did not perform cost‐effectiveness analysis because these outcomes have been evaluated in another study that performed a detailed cost analysis by pooling data from the three published RCTs comparing PFO closure with medical therapy (<a href="./references#CD009938-bbs2-0051" title="PickettC , VillinesT , FergusonM , HultenE . Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;D=emed11&amp;AN=71512311] ">Pickett 2014</a>). In that study the authors drew the conclusion that PFO closure is associated with higher medical expenditures related to procedural costs; however, this increase may be offset over time due to reduced event rates and the costs of long‐term medical treatment in people who do not undergo device closure (<a href="./references#CD009938-bbs2-0051" title="PickettC , VillinesT , FergusonM , HultenE . Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;D=emed11&amp;AN=71512311] ">Pickett 2014</a>). </p> </section> <section id="CD009938-sec-0078"> <h3 class="title" id="CD009938-sec-0078">Overall completeness and applicability of evidence</h3> <p>To date it is still unknown whether closure of a PFO is superior to medical therapy for preventing recurrent stroke after a cryptogenic stroke or TIA caused by presumed paradoxical embolism through a PFO. A meta‐analysis of observational studies published in 2012 demonstrated the potential benefit of PFO closure for preventing recurrent stroke and showed that the Amplatzer PFO occluder, which was the most common device, had advantageous safety features. The authors of that meta‐analysis noted several important limitations in the observational studies and highlighted the need for RCTs to clarify this question (<a href="./references#CD009938-bbs2-0011" title="AgarwalS , BajajNS , KumbhaniDJ , TuzcuEM , KapadiaSR . Meta‐analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovascular Interventions2012;5(7):777‐89. ">Agarwal 2012</a>). However, many people with PFO have been treated without evidence of benefit with different types of device. </p> <p>None of the three published RCTs comparing closure versus medical therapy provided evidence of any effect, because none of the trials reached statistical significance in achieving their primary endpoints on the ITT cohort. Particularly, both <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a> and <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> were underpowered to detect the difference in primary composite endpoints because of lower than expected event rates. However, all three trials showed a trend in favor of the device closure group. In the present meta‐analysis, we found no significant difference between device closure and medical therapy with respect to the prevention of the composite endpoint of recurrent stroke or TIA. However, we reported a possible benefit from the PFO closure when compared with medical therapy for preventing recurrent stroke. In the pooled analysis of hazard ratio, there was a trend of 62% risk reduction on recurrent stroke when the results of two trials using the Amplatzer device were synthesized (<a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>). The different result of the different primary outcome measure could be easily explained as TIA was a less clear‐cut endpoint than stroke and could be easily mimicked by other transient neurological events such as migraine, which might not be caused by paradoxical embolism. As a result, including TIA as a component of the primary outcome would increase the event rate but lead to dilution of effect at the same time. Our findings support the result of a recently published randomized study of three different devices (Amplatzer, Cardioseal‐STARFlex and Helex) implanted in people with cryptogenic stroke and PFO. This study, which did not compare closure with medical therapy, found few neurological events occurred in participants implanted with the Amplatzer device (<a href="./references#CD009938-bbs2-0031" title="HornungM , BertogSC , FrankeJ , IdD , TaaffeM , WunderlichN , et al. Long‐term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. European Heart Journal2013;34(43):3362‐9. ">Hornung 2013</a>). </p> <p>We conducted subgroup analysis for the primary composite endpoint, but failed to identify specific characteristics of people most likely to benefit from closure for secondary prevention. None of the features, such as younger age, presence of atrial septal aneurysm, substantial shunt size, previous vascular event, was identified as a high‐risk feature of future vascular events. Although the participants in the included trials could represent many people who undergo closure with off‐label devices, those who may be at highest risk for paradoxical embolism could have been hampered in the three RCTs, because those people with high‐risk PFO and their physicians may prefer to choose device closure and lead them to decline participation in a trial in order to avoid random allocation. </p> <p>We performed a safety analysis and found that closure was not associated with an increased rate of total adverse events as well as bleeding and myocardial infarction, when compared with medical therapy. However, we found that the rate of new onset atrial fibrillation was higher in the device closure group and, when stratified by device type, both the STARFlex and Amplatzer device increased the risk of atrial fibrillation. Meanwhile, the STARFlex device was associated with a higher risk for developing atrial fibrillation than was the Amplatzer device. This is in disagreement with another published meta‐analysis involving the same three trials (<a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a>). This could be explained because we included new onset minor atrial fibrillation in our analysis more than atrial fibrillation adjudicated as serious adverse events. </p> <p>In our review, we did not perform cost‐effectiveness analysis because these outcomes have been evaluated in another study that performed a detailed cost analysis by pooling data from the three published RCTs comparing PFO closure with medical therapy (<a href="./references#CD009938-bbs2-0051" title="PickettC , VillinesT , FergusonM , HultenE . Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;D=emed11&amp;AN=71512311] ">Pickett 2014</a>). They found that PFO closure is associated with higher medical expenditures related to procedural costs; however, this increase may be offset over time due to reduced event rates and the costs of long‐term medical treatment in people who do not undergo device closure (<a href="./references#CD009938-bbs2-0051" title="PickettC , VillinesT , FergusonM , HultenE . Cost analysis of percutaneous closure versus medical therapy for cryptogenic stroke patients with a patent foramen ovale. 37th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions', SCAI 2014 Las Vegas, NV United States. 2014. [EMBASE: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;D=emed11&amp;AN=71512311] ">Pickett 2014</a>). It is known that survivors of cryptogenic stroke are typically of a younger age, the effect of preventing vascular events may persist for their lifetime and accumulate over time. However, it is a remarkable fact that risks of an implanted device such as device‐related thrombus and arrhythmia would also accumulate over time. Unfortunately, none of the three published RCTs had a mean follow‐up duration longer than five years. For this reason, the interpretation of the results of the previous cost‐effectiveness analysis should still be cautious. </p> </section> <section id="CD009938-sec-0079"> <h3 class="title" id="CD009938-sec-0079">Quality of the evidence</h3> <p>We performed this systematic review and meta‐analysis of best available data of three published RCTs to compare both the efficacy and safety of device closure with medical therapy in people with PFO and a history of cryptogenic stroke, rigorously following the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009938-bbs2-0029" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We carried out broad searches for relevant studies, and it is unlikely that significant amounts of data remain unknown to us. We evaluated all three included trials and created 'Risk of bias' tables with descriptions and judgments for each of the studies. All three populations included in our analysis had similar baseline characteristics, which make them suitable for meta‐analysis. We did not use funnel plots and the Egger test to assess the existence of possible publication bias because there were only three trials included in our meta‐analysis. Because of a significant between‐group difference in follow‐up observation time, which resulted from different dropout rates between groups, we conducted point‐in‐time analyses and express the pooled risk estimates as risk ratios (RRs), as well as a pooled hazard ratio (HR) which account for time‐to‐event analysis. We performed all analyses on the ITT cohort using the random‐effects model (more conservative) regardless of the level of heterogeneity. We also performed a sensitivity analysis to provide a single true effect of closure using the Amplatzer PFO occluder. </p> <p>Risk of bias for all three included trials was deemed high. A possible lack of concealment of randomization occurred in <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>, so that some participants did not receive their randomly assigned treatment, which could lead to selection bias. As we know, a large number of people who were more likely to have PFO‐related vascular events have been preferentially treated with off‐label device closure, which may lead to difficulties recruiting to the studies and selection bias by excluding high‐risk PFO patients. In <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a>, selective reporting bias was introduced because the Clinical Events Committee discounted potential primary endpoint events more often in the medical therapy group than in the closure group. The major problem in terms of risk of bias is the high dropout rate compared with event rate in these trials and the difference in the dropout rate between the closure and the medical therapy group, which could result in unequal duration of exposure to the risk of recurrent vascular events (attrition bias). Our meta‐analysis was based on reported results, not individual participant data. If event rates differed in those with missing data in the closure and medical therapy groups, the complete case results may be misleading. </p> </section> <section id="CD009938-sec-0080"> <h3 class="title" id="CD009938-sec-0080">Potential biases in the review process</h3> <p>There are still some limitations in our present systematic review and meta‐analysis. Inclusion criteria, devices used, variations in the definitions of adverse events and the length of follow‐up differed among the three trials, making direct comparisons of treatment effects and safety difficult. Meanwhile, the evaluation of cryptogenic stroke in the trials was not standardized, which adds difficulty in precisely diagnosing paradoxical embolism and makes the baseline risks for paradoxical embolism between trials possibly different. Moreover, the primary endpoints were different among trials: we chose the recurrence of cerebrovascular events (composite of stroke or TIA), and recurrent stroke which is perhaps clinically most relevant to paradoxical embolism, as the primary endpoints in this meta‐analysis. Furthermore, in two of the studies (<a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a>; <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>), the type and dose of antithrombotic therapy in the medical therapy group was left to the treating physician's discretion and no RCTs directly and adequately compared closure versus a specified antithrombotic regimen. At the same time, the antiplatelet therapy in the closure group differed between the three trials, making the interpretation of the data difficult. In spite of the uncertainty of the optimal antithrombotic regimen, we did not have individual participant data available to perform the overall and subgroup analyses regarding the influence of the type and dose of antithrombotic treatment that participants received in each arm. Finally, we did not conduct an extensive search of the gray literature, including contacting manufacturers of the transcatheter closure devices, searching conference abstracts and contacting investigators and researchers in the field, which may lead to publication bias. </p> </section> <section id="CD009938-sec-0081"> <h3 class="title" id="CD009938-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>There were 14 meta‐analyses of the three RCTs comparing PFO closure versus medical therapy published recently, which had somewhat different results (<a href="./references#CD009938-bbs2-0016" title="CapodannoD , MilazzoG , VitaleL , DiStefanoD , DiSalvoM , GrassoC , et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta‐analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention2014;9(11):1342‐9. ">Capodanno 2014</a>; <a href="./references#CD009938-bbs2-0028" title="HakeemA , MarmagkiolisK , HaciogluY , UretskyBF , GundogduB , LeesarM , et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta‐analysis of randomized controlled trials. Cardiovascular Revascularization Medicine2013;14(6):349‐55. ">Hakeem 2013</a>; <a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a>; <a href="./references#CD009938-bbs2-0034" title="KitsiosGD , ThalerDE , KentDM . Potentially large yet uncertain benefits: a meta‐analysis of patent foramen ovale closure trials. Stroke2013;44(9):2640‐3. ">Kitsios 2013</a>; <a href="./references#CD009938-bbs2-0036" title="KwongJSW , LamY‐Y , YuC‐M . Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta‐analysis of randomized controlled trials. International Journal of Cardiology2013;168(4):4132‐8. ">Kwong 2013</a>; <a href="./references#CD009938-bbs2-0043" title="NagarajaV , RavalJ , EslickGD , BurgessD , DennissAR . Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta‐analysis of randomised trials. Heart, Lung and Circulation2013;22(11):903‐9. ">Nagaraja 2013</a>; <a href="./references#CD009938-bbs2-0044" title="NtaiosG , PapavasileiouV , MakaritsisK , MichelP . PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta‐analysis. International Journal of Cardiology2013;169(2):101‐5. ">Ntaios 2013</a>; <a href="./references#CD009938-bbs2-0049" title="PanditA , AryalMR , PanditAA , JalotaL , KantharajpurS , HakimFA , et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta‐analysis of randomised trials. Heart, Lung and Circulation2014;23(4):303‐8. ">Pandit 2014</a>; <a href="./references#CD009938-bbs2-0052" title="PinedaAM , NascimentoFO , YangSC , KirtaneAJ , SommerRJ , BeoharN . A meta‐analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular2013;82(6):968‐75. ">Pineda 2013</a>; <a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a>; <a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a>; <a href="./references#CD009938-bbs2-0057" title="SpencerFA , LopesLC , KennedySA , GuyattG . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open2014;4:e004282. [DOI: 10.1136/bmjopen‐2013‐004282] ">Spencer 2014</a>; <a href="./references#CD009938-bbs2-0061" title="UdellJA , OpotowskyAR , KhairyP , SilversidesCK , GladstoneDJ , O'GaraPT , et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology2014; Vol. 30, issue 10:1216‐24. ">Udell 2014</a>; <a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a>). In our meta‐analysis, the combined data from the three RCTs to date suggests that, while there was a trend towards improved outcomes with PFO closure (especially for the Amplatzer PFO occluder), there was no statistical significance in comparison to medical therapy. Our finding is in agreement with one published meta‐analysis (<a href="./references#CD009938-bbs2-0034" title="KitsiosGD , ThalerDE , KentDM . Potentially large yet uncertain benefits: a meta‐analysis of patent foramen ovale closure trials. Stroke2013;44(9):2640‐3. ">Kitsios 2013</a>), both in data synthesis and general interpretation of results. In comparison to our findings, five investigators did not support routine use of PFO closure devices for secondary prevention of cerebrovascular events based on negative overall results of their meta‐analyses (<a href="./references#CD009938-bbs2-0036" title="KwongJSW , LamY‐Y , YuC‐M . Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta‐analysis of randomized controlled trials. International Journal of Cardiology2013;168(4):4132‐8. ">Kwong 2013</a>; <a href="./references#CD009938-bbs2-0043" title="NagarajaV , RavalJ , EslickGD , BurgessD , DennissAR . Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta‐analysis of randomised trials. Heart, Lung and Circulation2013;22(11):903‐9. ">Nagaraja 2013</a>; <a href="./references#CD009938-bbs2-0057" title="SpencerFA , LopesLC , KennedySA , GuyattG . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open2014;4:e004282. [DOI: 10.1136/bmjopen‐2013‐004282] ">Spencer 2014</a>; <a href="./references#CD009938-bbs2-0061" title="UdellJA , OpotowskyAR , KhairyP , SilversidesCK , GladstoneDJ , O'GaraPT , et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology2014; Vol. 30, issue 10:1216‐24. ">Udell 2014</a>; <a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a>); two found a clear benefit of PFO closure (<a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a>; <a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a>); five were modestly inclined to support closure based on negative overall results but positive findings in an 'as‐treated' or 'per‐protocol' analysis (<a href="./references#CD009938-bbs2-0052" title="PinedaAM , NascimentoFO , YangSC , KirtaneAJ , SommerRJ , BeoharN . A meta‐analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular2013;82(6):968‐75. ">Pineda 2013</a>; <a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a>), or positive results in sensitivity analysis providing a separate true effect of closure using the Amplatzer device (<a href="./references#CD009938-bbs2-0016" title="CapodannoD , MilazzoG , VitaleL , DiStefanoD , DiSalvoM , GrassoC , et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta‐analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention2014;9(11):1342‐9. ">Capodanno 2014</a>: <a href="./references#CD009938-bbs2-0044" title="NtaiosG , PapavasileiouV , MakaritsisK , MichelP . PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta‐analysis. International Journal of Cardiology2013;169(2):101‐5. ">Ntaios 2013</a>; <a href="./references#CD009938-bbs2-0049" title="PanditA , AryalMR , PanditAA , JalotaL , KantharajpurS , HakimFA , et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta‐analysis of randomised trials. Heart, Lung and Circulation2014;23(4):303‐8. ">Pandit 2014</a>); one study did not support benefit or harm based on negative overall results but borderline effect in a 'per‐protocol' analysis (<a href="./references#CD009938-bbs2-0028" title="HakeemA , MarmagkiolisK , HaciogluY , UretskyBF , GundogduB , LeesarM , et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta‐analysis of randomized controlled trials. Cardiovascular Revascularization Medicine2013;14(6):349‐55. ">Hakeem 2013</a>). The differences in reported reviews can be attributed to the selection of primary outcome, risk estimates measure, data extraction and the statistical methodology (such as using a fixed‐effect or a random‐effects model, ITT or per‐protocol analysis, subgroup analysis or not, safety analysis or not). In our analysis, we selected the composite endpoint of ischemic stroke or TIA events as well as recurrent fatal or non‐fatal ischemic stroke as our primary outcome measures, and only <a href="./references#CD009938-bbs2-0001" title="FurlanAJ , ReismanM , MassaroJ , MauriL , AdamsH , AlbersGW , CLOSURE I investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. New England Journal of Medicine2012;366(11):991‐9. ">CLOSURE I 2012</a> and <a href="./references#CD009938-bbs2-0002" title="MeierB , KalesanB , MattleHP , KhattabAA , Hildick‐SmithD , DudekD , PC Trial investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. New England Journal of Medicine2013;368(12):1083‐91. ">PC 2013</a> were included in the meta‐analysis for composite endpoint of recurrent stroke or TIA because we could not extract data of composite of stroke or TIA from <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a>. However, three previous published studies chose the composite endpoint of each trial as their primary outcome and simply combined data of all three RCTs together (<a href="./references#CD009938-bbs2-0028" title="HakeemA , MarmagkiolisK , HaciogluY , UretskyBF , GundogduB , LeesarM , et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta‐analysis of randomized controlled trials. Cardiovascular Revascularization Medicine2013;14(6):349‐55. ">Hakeem 2013</a>; <a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a>; <a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a>). Three studies selected the composite endpoint of stroke or TIA as their primary outcome and performed meta‐analyses including <a href="./references#CD009938-bbs2-0003" title="CarrollJD , SaverJL , ThalerDE , SmallingRW , BerryS , MacDonaldLA , RESPECT investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. New England Journal of Medicine2013;368(12):1092‐100. ">RESPECT 2013</a> by simply using the available data on recurrent stroke as substitutes (<a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a>), or misunderstanding the meaning of composite endpoint by incorrectly adding numbers of participants with ischemic stroke or TIA events together (<a href="./references#CD009938-bbs2-0052" title="PinedaAM , NascimentoFO , YangSC , KirtaneAJ , SommerRJ , BeoharN . A meta‐analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular2013;82(6):968‐75. ">Pineda 2013</a>; <a href="./references#CD009938-bbs2-0061" title="UdellJA , OpotowskyAR , KhairyP , SilversidesCK , GladstoneDJ , O'GaraPT , et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology2014; Vol. 30, issue 10:1216‐24. ">Udell 2014</a>). As we discussed previously, the three included trials differed meaningfully in many aspects such as study design, device used, length of follow‐up and so on; we conducted a conservative point‐in‐time analysis that provides the binary calculation of RR, which is more realistic but sometimes underestimates the treatment effects. At the same time, we calculated risk estimates as pooled HR for time‐to‐event outcomes, which accounts for differential follow‐up intervals and participants who were lost to follow‐up. Except for <a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a>, the other reviews performed their meta‐analyses using risk estimates RR (OR) or HR separately. With respect to statistical methodology, all of the published reviews performed meta‐analyses on the ITT cohort, while several reviews carried out analyses on the per‐protocol cohort simultaneously (<a href="#CD009938-tbl-0005">Table 1</a>). Four studies performed meta‐analyses based on the fix‐effect model (<a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a>; <a href="./references#CD009938-bbs2-0044" title="NtaiosG , PapavasileiouV , MakaritsisK , MichelP . PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta‐analysis. International Journal of Cardiology2013;169(2):101‐5. ">Ntaios 2013</a>; <a href="./references#CD009938-bbs2-0049" title="PanditA , AryalMR , PanditAA , JalotaL , KantharajpurS , HakimFA , et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta‐analysis of randomised trials. Heart, Lung and Circulation2014;23(4):303‐8. ">Pandit 2014</a>; <a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a>); while two studies planned to use the random‐effects model in their protocol (<a href="./references#CD009938-bbs2-0016" title="CapodannoD , MilazzoG , VitaleL , DiStefanoD , DiSalvoM , GrassoC , et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta‐analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention2014;9(11):1342‐9. ">Capodanno 2014</a>; <a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a>). However, they used the fix‐effect model in the final analyses. Except for two studies (<a href="./references#CD009938-bbs2-0034" title="KitsiosGD , ThalerDE , KentDM . Potentially large yet uncertain benefits: a meta‐analysis of patent foramen ovale closure trials. Stroke2013;44(9):2640‐3. ">Kitsios 2013</a>; <a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a>), most of the published studies did not extract data from the texts and appendices of the included randomized trials correctly and comprehensively, which might lead to misleading results (<a href="#CD009938-tbl-0005">Table 1</a>). </p> <div class="table" id="CD009938-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses of RCTs comparing closure versus medical therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk estimates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects on ITT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects on per‐protocol or as treated cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Safety analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random‐effects model only</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data extraction from texts and appendices</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects of Amplatzer only RCTs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent stroke or TIA</p> <p>2. Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR and HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. RR 0.73 (0.45 to 1.17); HR 0.69 (0.43 to 1.13)</p> <p>2. RR 0.61 (0.29 to 1.27); HR 0.55 (0.26 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. RR 0.40 (0.14 to 1.19); HR 0.38 (0.14 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0028" title="HakeemA , MarmagkiolisK , HaciogluY , UretskyBF , GundogduB , LeesarM , et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta‐analysis of randomized controlled trials. Cardiovascular Revascularization Medicine2013;14(6):349‐55. ">Hakeem 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite of death, stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.48 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.43 to 1.00) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite endpoint of each trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.44 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.40 to 0.95) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.54 (0.29 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0034" title="KitsiosGD , ThalerDE , KentDM . Potentially large yet uncertain benefits: a meta‐analysis of patent foramen ovale closure trials. Stroke2013;44(9):2640‐3. ">Kitsios 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.26 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.16 to 1.70) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.38 (0.14 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0036" title="KwongJSW , LamY‐Y , YuC‐M . Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta‐analysis of randomized controlled trials. International Journal of Cardiology2013;168(4):4132‐8. ">Kwong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent stroke;</p> <p>2. Recurrent TIA;</p> <p>3. All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR or HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. OR 0.65 (0.36 to 1.20);</p> <p>2. HR 0.77 (0.45 to 1.32);</p> <p>3. OR 0.65 (0.23 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. OR 0.47 (0.22 to 1.02);</p> <p>2. HR 0.77 (0.45 to 1.32);</p> <p>3. OR 1.07 (0.11 to 9.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0043" title="NagarajaV , RavalJ , EslickGD , BurgessD , DennissAR . Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta‐analysis of randomised trials. Heart, Lung and Circulation2013;22(11):903‐9. ">Nagaraja 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned, perhaps recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.35 to 1.19) (data extraction from RESPECT study could not be found)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0044" title="NtaiosG , PapavasileiouV , MakaritsisK , MichelP . PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta‐analysis. International Journal of Cardiology2013;169(2):101‐5. ">Ntaios 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.37 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46 (0.21 to 0.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0052" title="PinedaAM , NascimentoFO , YangSC , KirtaneAJ , SommerRJ , BeoharN . A meta‐analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular2013;82(6):968‐75. ">Pineda 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.47 to 1.05) (data extraction from RESPECT study may be erroneous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.41 to 0.94) on as treated cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent vascular events;</p> <p>2. Death/vascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. HR 0.60 (0.36 to 0.98)</p> <p>2. HR 0.67 (0.44 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. HR 0.62 (0.38 to 1.00) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death/vascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.43 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.41 to 0.98) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.54 (0.29 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0061" title="UdellJA , OpotowskyAR , KhairyP , SilversidesCK , GladstoneDJ , O'GaraPT , et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology2014; Vol. 30, issue 10:1216‐24. ">Udell 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.50 to 1.07) (data extraction from RESPECT study may be erroneous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0057" title="SpencerFA , LopesLC , KennedySA , GuyattG . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open2014;4:e004282. [DOI: 10.1136/bmjopen‐2013‐004282] ">Spencer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.34 to 1.07) (data extraction may be erroneous for ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.32 to 1.38) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.44 (0.21 to 0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0049" title="PanditA , AryalMR , PanditAA , JalotaL , KantharajpurS , HakimFA , et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta‐analysis of randomised trials. Heart, Lung and Circulation2014;23(4):303‐8. ">Pandit 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.36 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.44 (0.21 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR and HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.37 to 1.19);</p> <p>HR 0.61 (0.34 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.32 to 1.38) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, but used fixed‐effect model in meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.48 (0.23 to 1.02)</p> <p>HR 0.44 (0.20 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0016" title="CapodannoD , MilazzoG , VitaleL , DiStefanoD , DiSalvoM , GrassoC , et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta‐analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention2014;9(11):1342‐9. ">Capodanno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.34 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.35 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, but used fixed‐effect model in meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.44 (0.20 to 0.95)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Recurrent stroke or TIA, recurrent vascular events: composite endpoint of ischemic stroke and TIA; death/vascular events: composite endpoint of death, ischemic stroke and TIA<br/> HR: hazard ratio<br/> ITT: intention‐to‐treat<br/> OR: odds ratio<br/> RR: risk ratio </p> </div> </div> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009938-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009938-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009938-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009938-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 1 Primary outcome measure: composite of recurrent stroke or TIA stratified by the type of device.." data-id="CD009938-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 1 Primary outcome measure: composite of recurrent stroke or TIA stratified by the type of device.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 2 Subgroup analyses according to age for the composite outcome." data-id="CD009938-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 2 Subgroup analyses according to age for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 3 Subgroup analyses according to gender for the composite outcome." data-id="CD009938-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 3 Subgroup analyses according to gender for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 4 Subgroup analyses according to the presence or absence of an atrial septal aneurysm for the composite outcome." data-id="CD009938-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 4 Subgroup analyses according to the presence or absence of an atrial septal aneurysm for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 5 Subgroup analyses according to the shunt size of PFO for the composite outcome." data-id="CD009938-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 5 Subgroup analyses according to the shunt size of PFO for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 6 Subgroup analyses according to the entry vascular events for the composite outcome." data-id="CD009938-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 6 Subgroup analyses according to the entry vascular events for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 7 Subgroup analyses according to baseline medical regimen for the composite outcome." data-id="CD009938-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome, Outcome 7 Subgroup analyses according to baseline medical regimen for the composite outcome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Primary outcome measure: recurrent stroke (non‐fatal or fatal), Outcome 1 Time‐to‐event analyses for recurrent stroke stratified by the type of device.." data-id="CD009938-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Primary outcome measure: recurrent stroke (non‐fatal or fatal), Outcome 1 Time‐to‐event analyses for recurrent stroke stratified by the type of device.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Primary outcome measure: recurrent stroke (non‐fatal or fatal), Outcome 2 Primary outcome measure: recurrent stroke stratified by the type of device studied.." data-id="CD009938-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Primary outcome measure: recurrent stroke (non‐fatal or fatal), Outcome 2 Primary outcome measure: recurrent stroke stratified by the type of device studied.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 1 Secondary outcome: all‐cause mortality at the end of follow‐up." data-id="CD009938-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 1 Secondary outcome: all‐cause mortality at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 2 Secondary outcome: total serious adverse events at the end of follow‐up." data-id="CD009938-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 2 Secondary outcome: total serious adverse events at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 3 Secondary outcome: the incidence of atrial fibrillation." data-id="CD009938-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 3 Secondary outcome: the incidence of atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 4 Secondary outcome: on the incidence of myocardial infarction." data-id="CD009938-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 4 Secondary outcome: on the incidence of myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 5 Secondary outcome: on the incidence of bleeding." data-id="CD009938-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding), Outcome 5 Secondary outcome: on the incidence of bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009938-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/urn:x-wiley:14651858:media:CD009938:CD009938-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_t/tCD009938-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Time‐to‐event analyses for composite of recurrent stroke or TIA, Outcome 1 Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied.." data-id="CD009938-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Time‐to‐event analyses for composite of recurrent stroke or TIA, Outcome 1 Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/media/CDSR/CD009938/image_n/nCD009938-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009938-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.45 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1323<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> <br/> (25 to 64) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (26 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.47</b> <br/> (0.17 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>414<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (9 to 69) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> <br/> (9 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TDC compared with medical therapy for preventing composite recurrent stroke or TIA in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009938-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: recurrent stroke (non‐fatal or fatal)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.29 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> <br/> (9 to 40) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (10 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.4</b> <br/> (0.14 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1394<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (5 to 40) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (5 to 39) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TDC compared with medical therapy for preventing recurrent stroke in people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009938-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack<br/> <b>Settings:</b> hospital, medical center<br/> <b>Intervention:</b> TDC<br/> <b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Medical therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>TDC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome: all‐cause mortality at the end of follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.23 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 16) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> <br/> (2 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome:total serious adverse events at the end of follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.04</b> <br/> (0.88 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b> <br/> (166 to 231) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>183 per 1000</b> <br/> (155 to 216) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Secondary outcome: the incidence of atrial fibrillation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.5</b> <br/> (1.47 to 8.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> <br/> (15 to 87) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> <br/> (15 to 84) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009938-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack </p> <p><b>Settings:</b> hospital, medical center </p> <p><b>Intervention:</b> TDC </p> <p><b>Comparison:</b> medical therapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for recurrent stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.55</b> </p> <p>(0.26 to 1.18)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2303<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for recurrent stroke stratified by the type of device ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.38</b> </p> <p>(0.14 to 1.02)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1394<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for composite of recurrent stroke or TIA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.69</b> </p> <p>(0.43 to 1.13)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1323<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.45</b> <br/> (0.16 to 1.28) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>414<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI:</b> Confidence interval;<b>HR:</b> hazard ratio </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">TDC compared with medical therapy for people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack: time‐to‐event analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009938-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses of RCTs comparing closure versus medical therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk estimates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects on ITT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects on per‐protocol or as treated cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Safety analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random‐effects model only</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Data extraction from texts and appendices</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effects of Amplatzer only RCTs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent stroke or TIA</p> <p>2. Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR and HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. RR 0.73 (0.45 to 1.17); HR 0.69 (0.43 to 1.13)</p> <p>2. RR 0.61 (0.29 to 1.27); HR 0.55 (0.26 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. RR 0.40 (0.14 to 1.19); HR 0.38 (0.14 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0028" title="HakeemA , MarmagkiolisK , HaciogluY , UretskyBF , GundogduB , LeesarM , et al. Safety and efficacy of device closure for patent foramen ovale for secondary prevention of neurological events: comprehensive systematic review and meta‐analysis of randomized controlled trials. Cardiovascular Revascularization Medicine2013;14(6):349‐55. ">Hakeem 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite of death, stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.48 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.43 to 1.00) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0033" title="KhanAR , Bin AbdulhakAA , SheikhMA , KhanS , ErwinPJ , et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic Stroke. Journal of the American College of Cardiology2013;6(12):1316–23. ">Khan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Composite endpoint of each trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.44 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.40 to 0.95) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.54 (0.29 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0034" title="KitsiosGD , ThalerDE , KentDM . Potentially large yet uncertain benefits: a meta‐analysis of patent foramen ovale closure trials. Stroke2013;44(9):2640‐3. ">Kitsios 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.26 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.16 to 1.70) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.38 (0.14 to 1.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0036" title="KwongJSW , LamY‐Y , YuC‐M . Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta‐analysis of randomized controlled trials. International Journal of Cardiology2013;168(4):4132‐8. ">Kwong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent stroke;</p> <p>2. Recurrent TIA;</p> <p>3. All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR or HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. OR 0.65 (0.36 to 1.20);</p> <p>2. HR 0.77 (0.45 to 1.32);</p> <p>3. OR 0.65 (0.23 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. OR 0.47 (0.22 to 1.02);</p> <p>2. HR 0.77 (0.45 to 1.32);</p> <p>3. OR 1.07 (0.11 to 9.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0043" title="NagarajaV , RavalJ , EslickGD , BurgessD , DennissAR . Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta‐analysis of randomised trials. Heart, Lung and Circulation2013;22(11):903‐9. ">Nagaraja 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not mentioned, perhaps recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.35 to 1.19) (data extraction from RESPECT study could not be found)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0044" title="NtaiosG , PapavasileiouV , MakaritsisK , MichelP . PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta‐analysis. International Journal of Cardiology2013;169(2):101‐5. ">Ntaios 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.37 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46 (0.21 to 0.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0052" title="PinedaAM , NascimentoFO , YangSC , KirtaneAJ , SommerRJ , BeoharN . A meta‐analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events. Catheterization and Cardiovascular2013;82(6):968‐75. ">Pineda 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.47 to 1.05) (data extraction from RESPECT study may be erroneous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.41 to 0.94) on as treated cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0053" title="Rengifo‐MorenoP , PalaciosIF , JunpaparpP , WitzkeCF , MorrisLD , Romero‐CorralA . Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta‐analysis of randomized controlled trials. European Heart Journal2013;34(43):3342–52. ">Rengifo‐Moreno 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Recurrent vascular events;</p> <p>2. Death/vascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. HR 0.60 (0.36 to 0.98)</p> <p>2. HR 0.67 (0.44 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. HR 0.62 (0.38 to 1.00) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0055" title="RiazIB , DhobleA , MizyedA , HsuCH , HusnainM , LeeJZ , et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta‐analysis of randomized clinical trials. BMC Cardiovascular Disorders2013;13:116. ">Riaz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death/vascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.43 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.41 to 0.98) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.54 (0.29 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0061" title="UdellJA , OpotowskyAR , KhairyP , SilversidesCK , GladstoneDJ , O'GaraPT , et al. Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses. Canadian Journal of Cardiology2014; Vol. 30, issue 10:1216‐24. ">Udell 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke or TIA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.50 to 1.07) (data extraction from RESPECT study may be erroneous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0057" title="SpencerFA , LopesLC , KennedySA , GuyattG . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open2014;4:e004282. [DOI: 10.1136/bmjopen‐2013‐004282] ">Spencer 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.34 to 1.07) (data extraction may be erroneous for ITT analysis)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.32 to 1.38) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.44 (0.21 to 0.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0049" title="PanditA , AryalMR , PanditAA , JalotaL , KantharajpurS , HakimFA , et al. PFO occluder device may prevent recurrent stroke in patients with patent foramen ovale and cryptogenic stroke: a meta‐analysis of randomised trials. Heart, Lung and Circulation2014;23(4):303‐8. ">Pandit 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.36 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.44 (0.21 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0064" title="WolfrumM , FroehlichGM , KnappG , CasaubonLK , DiNicolantonioJJ , LanskyAJ , et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta‐analysis. Heart2014;100(5):389‐95. ">Wolfrum 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR and HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.37 to 1.19);</p> <p>HR 0.61 (0.34 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.66 (0.32 to 1.38) on per‐protocol cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, but used fixed‐effect model in meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.48 (0.23 to 1.02)</p> <p>HR 0.44 (0.20 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009938-bbs2-0016" title="CapodannoD , MilazzoG , VitaleL , DiStefanoD , DiSalvoM , GrassoC , et al. Updating the evidence on patent foramen ovale closure versus medical therapy in patients with cryptogenic stroke: a systematic review and comprehensive meta‐analysis of 2,303 patients from three randomised trials and 2,231 patients from 11 observational studies. EuroIntervention2014;9(11):1342‐9. ">Capodanno 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62 (0.34 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.35 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, but used fixed‐effect model in meta‐analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.44 (0.20 to 0.95)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Recurrent stroke or TIA, recurrent vascular events: composite endpoint of ischemic stroke and TIA; death/vascular events: composite endpoint of death, ischemic stroke and TIA<br/> HR: hazard ratio<br/> ITT: intention‐to‐treat<br/> OR: odds ratio<br/> RR: risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Meta‐analyses of RCTs comparing closure versus medical therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/full#CD009938-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009938-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome measure: composite of recurrent stroke or TIA stratified by the type of device. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.45, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.48, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.17, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analyses according to age for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Age &lt; 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.12, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Age ≥ 45 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.28, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Subgroup analyses according to gender for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.56, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Subgroup analyses according to the presence or absence of an atrial septal aneurysm for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Presence of ASA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.22, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Absence of ASA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.47, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Subgroup analyses according to the shunt size of PFO for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Trace or moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.52, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Substantial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.09, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subgroup analyses according to the entry vascular events for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.48, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 TIA or systemic embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.30, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Subgroup analyses according to baseline medical regimen for the composite outcome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Antiplatelet alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.29, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Anticoagulant alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.28, 3.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary outcome measure: composite of recurrent stroke or TIA; subgroup analyses for the composite outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009938-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Primary outcome measure: recurrent stroke (non‐fatal or fatal)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time‐to‐event analyses for recurrent stroke stratified by the type of device. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.26, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.41, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.14, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Primary outcome measure: recurrent stroke stratified by the type of device studied. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.28, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.43, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.13, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Primary outcome measure: recurrent stroke (non‐fatal or fatal)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009938-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary outcome: all‐cause mortality at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.23, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.12, 9.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: total serious adverse events at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.88, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.90, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secondary outcome: the incidence of atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [1.47, 8.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.92 [2.40, 26.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.05, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Secondary outcome: on the incidence of myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [0.44, 18.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Secondary outcome: on the incidence of bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.47, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [0.82, 8.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.21, 5.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Secondary outcome:all‐cause mortality;serious adverse events (atrial fibrillation, myocardial infarction and bleeding)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009938-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Time‐to‐event analyses for composite of recurrent stroke or TIA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 STARFlex septal closure system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>909</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.45, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Amplatzer PFO occluder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.16, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Time‐to‐event analyses for composite of recurrent stroke or TIA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009938.pub2/references#CD009938-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009938.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009938-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009938-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009938-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD009938-note-0001">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009938\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009938\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009938\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009938\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009938\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009938.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009938.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009938.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009938.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009938.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726920246"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009938.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726920251"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009938.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9f6d8f05f480',t:'MTc0MDcyNjkyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 